Samuel T. Wilkinson, MD
Advertisement
Articles by Samuel T. Wilkinson, MD
Experts present the results of a retrospective analysis of patients who received IV ketamine for TRD over a timeframe of up to 2 years.
What is the efficacy of ECT for the treatment of dementia?
Samuel T. Wilkinson, MD, discusses the risks and benefits, as well as the challenges of clinical implementation of esketamine, for treatment-resistant depression.
Advertisement
Latest Updated Articles
The Effects of Multidose Ketamine Treatment on Cognitive Performance Over Time in Patients With TRDPublished: June 25th 2024 | Updated:
What Is the Deal With Esketamine?Published: April 6th 2020 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 4, 2025
2
New Year’s Resolutions and Bipolar Disorder: Insights from Jo Hughes, DSMc, PA-C, CAQ-PSYCH
3
This Year In Major Depressive Disorder
4
Phase 2 Proof-Of-Concept Study Evaluating BHV-7000 for Major Depressive Disorder Fails to Meet Primary Endpoint
5